CON: Procalcitonin does not have clinical utility in children with community-acquired pneumonia

Area of Science:

• Pediatric infectious diseases
• Biomarker-guided therapy
• Clinical diagnostics

Background:

• Procalcitonin (PCT) is a biomarker used to guide antibiotic therapy for lower respiratory tract infections (LRTI).
• Most clinical evidence supporting PCT use in LRTI management is derived from adult populations.
• Significant gaps exist in understanding PCT's role in pediatric populations.

Purpose of the Study:

• To evaluate the clinical impact and optimal implementation of procalcitonin (PCT) testing in pediatric patients with lower respiratory tract infections (LRTI).
• To address the lack of data regarding age-appropriate PCT cut-offs, diagnostic accuracy in immunocompromised children, and benefits beyond existing diagnostics.

Main Methods:

• Review of existing clinical studies and data on procalcitonin (PCT) use in pediatric LRTI.
• Analysis of evidence gaps concerning PCT's diagnostic accuracy, subgroup benefits, and comparative value against rapid molecular diagnostics.

Main Results:

• Limited clinical studies evaluate PCT's impact on managing LRTI in children.
• Insufficient data exists on age-specific PCT thresholds, performance in immunocompromised pediatric patients, and its added value over current rapid diagnostics.
• Optimal strategies for implementing PCT-guided treatment in pediatric settings remain unclear.

Conclusions:

• There is currently insufficient evidence to support the routine use of procalcitonin (PCT) for guiding the management of pediatric pneumonia.
• Further research is needed to establish the utility, optimal application, and cost-effectiveness of PCT in pediatric respiratory infections.